tiprankstipranks
Foghorn Therapeutics Unveils Clinical Pipeline Progress
PremiumCompany AnnouncementsFoghorn Therapeutics Unveils Clinical Pipeline Progress
1M ago
Foghorn Therapeutics announces first patient dosed with FHD-909
Premium
The Fly
Foghorn Therapeutics announces first patient dosed with FHD-909
1M ago
Foghorn Therapeutics price target raised to $9 from $6 at Morgan Stanley
Premium
The Fly
Foghorn Therapeutics price target raised to $9 from $6 at Morgan Stanley
2M ago
Foghorn Therapeutics reports Q2 EPS (45c), consensus (65c)
PremiumThe FlyFoghorn Therapeutics reports Q2 EPS (45c), consensus (65c)
4M ago
Foghorn Therapeutics Unveils Strategic Plans to Investors
Premium
Company Announcements
Foghorn Therapeutics Unveils Strategic Plans to Investors
6M ago
Foghorn Therapeutics prices 12.7M shares at $5.51 in registered direct offering
Premium
The Fly
Foghorn Therapeutics prices 12.7M shares at $5.51 in registered direct offering
6M ago
Foghorn Therapeutics appoints Humer as Chief Financial Officer
PremiumThe FlyFoghorn Therapeutics appoints Humer as Chief Financial Officer
7M ago
Foghorn Therapeutics Unveils Cancer Research Breakthroughs
Premium
Company Announcements
Foghorn Therapeutics Unveils Cancer Research Breakthroughs
8M ago
Foghorn Therapeutics Unveils New Investor Presentation
Premium
Company Announcements
Foghorn Therapeutics Unveils New Investor Presentation
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100